Drug news
Ortho Dermatologies re-files Duobrii at FDA as a proposed treatment for psoriasis.
Ortho Dermatologics has resubmitted an application to market its plaque psoriasis lotion Duobrii in the US. The move follows receipt of a complete response letter from the FDA in June, that raised questions regarding the drug�s pharmacokinetic data but did not specify any deficiencies relating to clinical efficacy or safety.